TY - JOUR
T1 - Current Treatment Strategies for Tricuspid Regurgitation
AU - Al-Hijji, Mohammed
AU - Fender, Erin A.
AU - El Sabbagh, Abdallah
AU - Holmes, David R.
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media, LLC.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Purpose of Review: Tricuspid regurgitation is common; however, recognition and diagnosis, clinical outcomes, and management strategies are poorly defined. Here, we will describe the etiology and natural history of tricuspid regurgitation (TR), evaluate existing surgical outcomes data, and review the evolving field of percutaneous interventions to treat TR. Recent Findings: Previously, the only definitive corrective therapy for TR was surgical valve repair or replacement which is associated with significant operative mortality. Advances in percutaneous valve repair techniques are now being translated to the tricuspid valve. These novel interventions may offer a lower-risk alternative treatment in patients at increased surgical risk. Summary: Significant TR adversely impacts survival. Surgery remains the only proven therapy for treatment of TR and may be underutilized due to mixed outcomes data. Early experience with percutaneous interventions is promising, but large clinical experience is lacking. Further study will be required before these therapies are introduced into broader clinical practice.
AB - Purpose of Review: Tricuspid regurgitation is common; however, recognition and diagnosis, clinical outcomes, and management strategies are poorly defined. Here, we will describe the etiology and natural history of tricuspid regurgitation (TR), evaluate existing surgical outcomes data, and review the evolving field of percutaneous interventions to treat TR. Recent Findings: Previously, the only definitive corrective therapy for TR was surgical valve repair or replacement which is associated with significant operative mortality. Advances in percutaneous valve repair techniques are now being translated to the tricuspid valve. These novel interventions may offer a lower-risk alternative treatment in patients at increased surgical risk. Summary: Significant TR adversely impacts survival. Surgery remains the only proven therapy for treatment of TR and may be underutilized due to mixed outcomes data. Early experience with percutaneous interventions is promising, but large clinical experience is lacking. Further study will be required before these therapies are introduced into broader clinical practice.
KW - Percutaneous valve repair
KW - Transcatheter valve replacement
KW - Tricuspid regurgitation
KW - Tricuspid valve surgery
KW - Valvular heart disease
UR - http://www.scopus.com/inward/record.url?scp=85029572300&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029572300&partnerID=8YFLogxK
U2 - 10.1007/s11886-017-0920-4
DO - 10.1007/s11886-017-0920-4
M3 - Review article
C2 - 28913730
AN - SCOPUS:85029572300
SN - 1523-3782
VL - 19
JO - Current cardiology reports
JF - Current cardiology reports
IS - 11
M1 - 106
ER -